Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ernestina Marianna De Francesco, Francesca Cirillo, Veronica Vella, Antonino Belfiore, Marcello Maggiolini & Rosamaria Lappano. (2022) Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets 26:6, pages 513-535.
Read now
Read now
Peipei Liu, Wenhui Li, Yuanyuan Hu & Youhong Jiang. (2018) Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer. OncoTargets and Therapy 11, pages 5485-5498.
Read now
Read now
Yang Gao, Qing Ma, Yan-Bin Ma, Liang Ding, Xiao-Long Xu, De-Fei Wei, Lei Wei & Jing-Wei Zhang. (2018) Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastructural Pathology 42:1, pages 49-54.
Read now
Read now
Nelson Rangel, Victoria E Villegas & Milena Rondón-Lagos. (2017) Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Breast Cancer: Targets and Therapy 9, pages 537-550.
Read now
Read now
Giuliana De Gregoriis, Juliene Antonio Ramos, Priscila Valverde Fernandes, Giselle Maria Vignal, Rafael Canfield Brianese, Dirce Maria Carraro, Alvaro N. Monteiro, Claudio José Struchiner, Guilherme Suarez-Kurtz, Rosane Vianna-Jorge & Marcelo Alex de Carvalho. (2017) DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. Cancer Biology & Therapy 18:6, pages 439-449.
Read now
Read now
Articles from other publishers (34)
Nikhil Ponnoor Anto, Amitha Muraleedharan & Rashmi Mittal. 2023. Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer. Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer
47
72
.
Zimiao Luo, Sunyi Wu, Jianfen Zhou, Weixia Xu, Qianzhu Xu, Linwei Lu, Cao Xie, Yu Liu & Weiyue Lu. (2023) All-stage targeted therapy for the brain metastasis from triple-negative breast cancer. Acta Pharmaceutica Sinica B 13:1, pages 359-371.
Crossref
Crossref
Zimiao Luo, Linwei Lu, Weixia Xu, Nana Meng, Sunyi Wu, Jianfen Zhou, Qianzhu Xu, Cao Xie, Yu Liu & Weiyue Lu. (2022) In vivo self-assembled drug nanocrystals for metastatic breast cancer all-stage targeted therapy. Journal of Controlled Release 346, pages 32-42.
Crossref
Crossref
Xiao Luo & Hui Wang. (2021) LINC00514 upregulates CCDC71L to promote cell proliferation, migration and invasion in triple‐negative breast cancer by sponging miR-6504-5p and miR-3139. Cancer Cell International 21:1.
Crossref
Crossref
Domenico Ribatti, Tiziana Annese & Roberto Tamma. (2021) Controversial role of mast cells in breast cancer tumor progression and angiogenesis. Clinical Breast Cancer 21:6, pages 486-491.
Crossref
Crossref
Giacomo Barchiesi, Michela Roberto, Monica Verrico, Patrizia Vici, Silverio Tomao & Federica Tomao. (2021) Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Frontiers in Oncology 11.
Crossref
Crossref
Ha Thi Thu Do & Jungsook Cho. (2020) Involvement of the ERK/HIF-1α/EMT Pathway in XCL1-Induced Migration of MDA-MB-231 and SK-BR-3 Breast Cancer Cells. International Journal of Molecular Sciences 22:1, pages 89.
Crossref
Crossref
Saba Malekian, Marveh Rahmati, Soyar Sari, Monireh Kazemimanesh, Raheleh Kheirbakhsh, Ahad Muhammadnejad & Saeid Amanpour. (2020) Expression of Diverse Angiogenesis Factor in Different Stages of the 4T1 Tumor as a Mouse Model of Triple-Negative Breast Cancer. Advanced Pharmaceutical Bulletin 10:2, pages 323-328.
Crossref
Crossref
Susumu Rokudai. 2020. Immune Mediators in Cancer. Immune Mediators in Cancer
297
303
.
Xiaolong Wang, Tong Chen, Yan Zhang, Ning Zhang, Chen Li, Yaming Li, Ying Liu, Hanwen Zhang, Wenjing Zhao, Bing Chen, Lijuan Wang & Qifeng Yang. (2019) Long noncoding RNA Linc00339 promotes triple‐negative breast cancer progression through miR‐377‐3p/HOXC6 signaling pathway. Journal of Cellular Physiology 234:8, pages 13303-13317.
Crossref
Crossref
Chu Tang, Yang Du, Qian Liang, Zhen Cheng & Jie Tian. (2019)
A selenium-containing selective histone deacetylase 6 inhibitor for targeted
in vivo
breast tumor imaging and therapy
. Journal of Materials Chemistry B 7:22, pages 3528-3536.
Crossref
Crossref
Yaqin Shi, Juan Jin, Xin Wang, Wenfei Ji & Xiaoxiang Guan. (2019) DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. Neoplasia 21:6, pages 533-544.
Crossref
Crossref
Yujie Zhang, Xi Zhu, Xinli Chen, Qinjun Chen, Wenxi Zhou, Qin Guo, Yifei Lu, Chao Li, Yu Zhang, Donghui Liang, Tao Sun, Xunbin Wei & Chen Jiang. (2019) Activated Platelets‐Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer. Advanced Functional Materials 29:13, pages 1806620.
Crossref
Crossref
Emmanuel N. Kontomanolis, Zacharias Fasoulakis, Valentinos Papamanolis, Sofia Koliantzaki, Georgios Dimopoulos & Nikolaos J. Kambas. (2019) The Impact of microRNAs in Breast Cancer Angiogenesis and Progression. MicroRNA 8:2, pages 101-109.
Crossref
Crossref
Jordan M. ReeseElizabeth S. BruinsmaAdam W. NelsonIgor ChernukhinJason S. CarrollYing LiMalayannan SubramaniamVera J. SumanVivian NegronDavid G. MonroeJames N. Ingle, Matthew P. Goetz & John R. Hawse. (2018) ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis. Proceedings of the National Academy of Sciences 115:41.
Crossref
Crossref
Eisuke Horigome, Michiru Fujieda, Tadashi Handa, Ayaka Katayama, Masashi Ito, Ami Ichihara, Daiki Tanaka, Navchaa Gombodorj, Shinji Yoshiyama, Arito Yamane, Keiichi Yamada, Jun Horiguchi, Kazuo Shinozuka, Tetsunari Oyama, Masahiko Nishiyama & Susumu Rokudai. (2018) Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget 9:77, pages 34554-34566.
Crossref
Crossref
Liang Li, Shuchen Liu, Liyuan Liu, Zhongbing Ma, Man Feng, Chunmiao Ye, Wenzhong Zhou, Yongjiu Wang, Lu Liu, Fei Wang, Lixiang Yu, Fei Zhou, Yujuan Xiang, Shuya Huang, Qinye Fu, Qiang Zhang, Dezong Gao & Zhigang Yu. (2018) Impact of phosphorylated insulin‑like growth factor‑1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy. Experimental and Therapeutic Medicine.
Crossref
Crossref
Chu Tang, Yang Du, Qian Liang, Zhen Cheng & Jie Tian. (2018) Development of a Novel Ferrocenyl Histone Deacetylase Inhibitor for Triple-Negative Breast Cancer Therapy. Organometallics 37:14, pages 2368-2375.
Crossref
Crossref
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif & Yadollah Omidi. (2018) In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. BioImpacts 9:1, pages 45-56.
Crossref
Crossref
Elke J. A. H. van Beek, Jonathan M. Hernandez, Debra A. Goldman, Jeremy L. Davis, Kaitlin McLaughlin, R. Taylor Ripley, Teresa S. Kim, Laura H. Tang, Jaclyn F. Hechtman, Jian Zheng, Marinela Capanu, Nikolaus Schultz, David M. Hyman, Marc Ladanyi, Michael F. Berger, David B. Solit, Yelena Y. Janjigian & Vivian E. Strong. (2018) Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology 25:7, pages 2027-2033.
Crossref
Crossref
Jun-Xia Zhang, Jiao-Mei Guo, Ting-Ting Zhang, Hong-Jun Lin, Nai-Song Qi, Zhen-Guo Li, Ji-Chun Zhou & Zhen-Zhong Zhang. (2018) Antiproliferative Phenothiazine Hybrids as Novel Apoptosis Inducers against MCF-7 Breast Cancer. Molecules 23:6, pages 1288.
Crossref
Crossref
Yuki InoueMasamitsu ShimazawaShinsuke NakamuraShinsuke TakataYuhei HashimotoHiroshi IzawaTomomi MasudaKazuhiro TsurumaTomohisa SakaueHironao NakayamaShigeki HigashiyamaHideaki Hara. (2018) Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology 38:1, pages 174-185.
Crossref
Crossref
Jiali Wu, Zeyu Shuang, Jianfu Zhao, Hailin Tang, Peng Liu, Lijuan Zhang, Xiaoming Xie & Xiangsheng Xiao. (2018) Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomedicine & Pharmacotherapy 97, pages 1275-1281.
Crossref
Crossref
Katharina Gohr, Alexandra Hamacher, Laura H. Engelke & Matthias U. Kassack. (2017) Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer 17:1.
Crossref
Crossref
Jordan M. Reese, Elizabeth S. Bruinsma, David G. Monroe, Vivian Negron, Vera J. Suman, James N. Ingle, Matthew P. Goetz & John R. Hawse. (2017) ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget 8:57, pages 96506-96521.
Crossref
Crossref
Litao Liu, Wenlan Liu, Lili Wang, Ting Zhu, Jianhua Zhong & Ni Xie. (2017) Hypoxia‑inducible factor 1 mediates intermittent hypoxia‑induced migration of human breast cancer MDA‑MB‑231 cells. Oncology Letters.
Crossref
Crossref
Anca Maria Cimpean, Roberto Tamma, Simona Ruggieri, Beatrice Nico, Alina Toma & Domenico Ribatti. (2017) Mast cells in breast cancer angiogenesis. Critical Reviews in Oncology/Hematology 115, pages 23-26.
Crossref
Crossref
Lingshuang Lü, Xuhua Mao, Peiyi Shi, Biyu He, Kun Xu, Simin Zhang & Jianming Wang. (2017) MicroRNAs in the prognosis of triple-negative breast cancer. Medicine 96:22, pages e7085.
Crossref
Crossref
Hongyan Jia, Cristina I. Truica, Bin Wang, Yanhong Wang, Xingcong Ren, Harold A. Harvey, Jianxun Song & Jin-Ming Yang. (2017) Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resistance Updates 32, pages 1-15.
Crossref
Crossref
Lee Yueh Jia, Muthu K. Shanmugam, Gautam Sethi & Anupam Bishayee. (2016) Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anti-Cancer Drugs 27:3, pages 147-155.
Crossref
Crossref
Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, Ciprian Tomuleasa, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar & Ioana Berindan-Neagoe. (2016) Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. Expert Reviews in Molecular Medicine 18.
Crossref
Crossref
Nataly Shtraizent, Hiroshi Matsui, Alla Polotskaia & Jill Bargonetti. (2015) Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. International Journal of Environmental Research and Public Health 13:1, pages 22.
Crossref
Crossref
Taotao Ling, My Tran, Miguel A. González, Lekh Nath Gautam, Michele Connelly, Rachael K. Wood, Iram Fatima, Gustavo Miranda-Carboni & Fatima Rivas. (2015) (+)-Dehydroabietylamine derivatives target triple-negative breast cancer. European Journal of Medicinal Chemistry 102, pages 9-13.
Crossref
Crossref
Vahid Bemanian, Torill Sauer, Joel Touma, Bjørn Arne Lindstedt, Ying Chen, Hilde Presterud Ødegård, Katja Marjaana Vetvik, Ida Rashida Bukholm & Jürgen Geisler. (2015) The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer. PLOS ONE 10:8, pages e0134398.
Crossref
Crossref